Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I Non–Small-Cell Lung Cancer Five-Year Mature Results

Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I... Brief Repotr Stereotactic Body Radiotherapy Using a Radiobiology-Based  Regimen for Stage I Non–Small-Cell Lung Cancer Five-Year Mature Results Yuta Shibamoto, MD, PhD,* Chisa Hashizume, MD,† Fumiya Baba, MD, PhD,* Shiho Ayakawa, MD, PhD,‡ Akifumi Miyakawa, MD, PhD,* Taro Murai, MD, PhD,* Taiki Takaoka, MD,* Yukiko Hattori, MD,* and Ryuji Asai, MD, PhD§ tereotactic body radiotherapy (SBRT) is now the first Introduction: Although the protocol of 48 Gy in four fractions over Schoice of treatment for medically inoperable patients with 4 days has been most often employed in stereotactic body radiother- stage I non–small-cell lung cancer (NSCLC) and operable apy (SBRT) for stage I non–small-cell lung cancer in Japan, higher 1–3 patients who refuse surgery. Recently reported results sug- doses are necessary to control larger tumors, and interfraction inter- 4–7 gest that SBRT and surgery yield nearly equivalent outcome. vals should be longer than 24 hours to take advantage of reoxygen- Owing to the relatively short history, however, the vast major- ation. We report the final results of our study testing the following ity of previously published data of SBRT, including those in regimen: for tumors less than 1.5, 1.5–3, and greater than 3 cm in 3,7–10 very recent publications, are middle-term 3-year data. To diameter, 44, 48, and 52 Gy, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I Non–Small-Cell Lung Cancer Five-Year Mature Results

Journal of Thoracic Oncology , Volume 10 (6) – Jun 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/stereotactic-body-radiotherapy-using-a-radiobiology-based-regimen-for-3XUA2bumSp

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000525
pmid
26001145
Publisher site
See Article on Publisher Site

Abstract

Brief Repotr Stereotactic Body Radiotherapy Using a Radiobiology-Based  Regimen for Stage I Non–Small-Cell Lung Cancer Five-Year Mature Results Yuta Shibamoto, MD, PhD,* Chisa Hashizume, MD,† Fumiya Baba, MD, PhD,* Shiho Ayakawa, MD, PhD,‡ Akifumi Miyakawa, MD, PhD,* Taro Murai, MD, PhD,* Taiki Takaoka, MD,* Yukiko Hattori, MD,* and Ryuji Asai, MD, PhD§ tereotactic body radiotherapy (SBRT) is now the first Introduction: Although the protocol of 48 Gy in four fractions over Schoice of treatment for medically inoperable patients with 4 days has been most often employed in stereotactic body radiother- stage I non–small-cell lung cancer (NSCLC) and operable apy (SBRT) for stage I non–small-cell lung cancer in Japan, higher 1–3 patients who refuse surgery. Recently reported results sug- doses are necessary to control larger tumors, and interfraction inter- 4–7 gest that SBRT and surgery yield nearly equivalent outcome. vals should be longer than 24 hours to take advantage of reoxygen- Owing to the relatively short history, however, the vast major- ation. We report the final results of our study testing the following ity of previously published data of SBRT, including those in regimen: for tumors less than 1.5, 1.5–3, and greater than 3 cm in 3,7–10 very recent publications, are middle-term 3-year data. To diameter, 44, 48, and 52 Gy,

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2015

References